Sage Therapeutics, Inc. (NASDAQ:SAGE) management will conduct a conference call for 10th August 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.sagerx.com
Earnings Expectation
Sage Therapeutics, Inc. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, SAGE is expected to report 2Q20 loss of $ 2.66 per share from revenue of $ 0.89 million.
For the full year, analysts anticipate top line of $ 9.58 million, while looking forward to loss of $ 10.01 per share bottom line.
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The companys product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders.
